Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010

Launched by GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO · Jun 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at patients with a condition called Primary Immune Thrombocytopenia (ITP), who have had their spleen removed (a surgery known as splenectomy) between January 1, 2010, and December 31, 2022. Researchers want to understand the outcomes of these patients by collecting and analyzing their medical information from this time period. The study aims to enroll participants over the next six months and will follow them for at least a year to see how they are doing after the surgery.

To be eligible for this study, participants must be at least 18 years old and diagnosed with primary ITP according to specific medical guidelines. There are no other groups excluded from participating. While the study is not yet recruiting, those who join can expect to have their health information reviewed and used to help improve understanding of ITP and its treatment through splenectomy. This research could provide valuable insights that may benefit future patients with the same condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged ≥ 18 years
• • Patients with primary ITP according to international criteria \[2\], who underwent to splenectomy from 01/01/2010 to 12/31/2022.
• • Obtaining Informed Consent.
• Exclusion Criteria:
• • none